Products
Elotuzumab Biosimilar Monoclonal Antibody (SLAMF7) for Research
Pre-Made Elotuzumab biosimilar, Whole mAb, Anti-SLAMF7/CS1 Antibody: Anti-19A/CD319/CRACC therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Elotuzumab, sold under the brand name Empliciti, is a humanized IgG1 monoclonal antibody medication used in combination with lenalidomide and dexamethasone, for adults that have received 1 to 3 prior therapies for the treatment of multiple myeloma. It is also indicated for adult patients in combination with pomalidomide and dexamethasone, who have received 2 prior therapies including lenalidomide and a protease inhibitor. Administration of elotuzumab is done intravenously. Each intravenous injection of elotuzumab should be premedicated with dexamethasone, diphenhydramine, ranitidine and acetaminophen. It is being developed by Bristol Myers Squibb and AbbVie.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-172-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Elotuzumab biosimilar, Whole mAb, Anti-SLAMF7/CS1 Antibody: Anti-19A/CD319/CRACC therapeutic antibody |
| INN Name | Elotuzumab |
| Target | CS1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | NFD |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2008 |
| Year Recommended | 2009 |
| Companies | AbbVie;Australasian Leukaemia & Lymphoma Group;Bristol-Myers Squibb;PDL BioPharma |
| Conditions Approved | Multiple myeloma |
| Conditions Active | na |
| Conditions Discontinued | na |
| Development Tech | na |
About target - SLAMF7
1. Protein SLAM family member 7
2. Gene SLAMF7
3. Organism Homo sapiens (Human)
Function
Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform 1 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway (PubMed:11698418).
Positively regulates NK cell functions by a mechanism dependent on phosphorylated SH2D1B. Downstream signaling implicates PLCG1, PLCG2 and PI3K (PubMed:16339536).
In addition to heterotypic NK cells-target cells interactions also homotypic interactions between NK cells may contribute to activation. However, in the absence of SH2D1B, inhibits NK cell function. Acts also inhibitory in T-cells (By similarity).
May play a role in lymphocyte adhesion (PubMed:11802771).
In LPS-activated monocytes negatively regulates production of proinflammatory cytokines (PubMed:23695528).
Isoform 3 does not mediate any NK cell activation.
Miscellaneous
Proposed to be involved in systemic lupus erythematosus (SLE) disease process.
